Hiperglisemide Nadir Bir Neden: Latent Otoimmun Erişkin Diyabeti

Öz

Dünyada ve Türkiye’de hızla artmakta olan diyabetes mellitus (DM), insülinin etkisinde, insülin sekresyonunda veya her iki defektin sonucunda ortaya çıkan hiperglisemi ile seyreden metabolizma hastalığıdır. Diyabet sınıflamasında primer ve sekonder olmak üzere diyabet formları bulunmaktadır. Özellikle tip 1 DM bazı dönemlerde pik yapsa da her yaşta görülebilir (1). Erişkinin latent otoimmun diyabeti (LADA) olarak tanımladığımız, genellikle 25-30 yaş üstü yavaş başlangıçlı, hafif seyirli olan pankreas beta hücre adacık fonksiyon kaybı ile giden hiperglisemik metabolizma hastalığıdır. Bu yazımızda 47 yaşında tip 2 DM ön tanısı ile yatışı yapılan ancak LADA tanısı alan vakamızı sunduk. Olgu sunumu için hastadan 20 aralık 2018 tarihinde onam alınmıştır.

Anahtar Kelimeler

• Diyabetes mellitus,insülin,LADA

A Rare Of Cause In Hyperglisemi: Latent Otoimmun Adult Diabetes

Öz

Rapidly growing in the world and Turkey diabetes mellitus (DM), the effect of insulin, characterized by hyperglycemia, insulin secretion, or the metabolic defect is the result you both diseases. Diabetes classification includes primary and secondary forms of diabetes. In the particulary type 1 DM may be seen at all ages, even if peaked in some periods (1). Latent Autoimmune Diabetes in Adults (LADA), pancreatic beta cell with slow onset and mild course, usually over 25-30 years old, is a hyperglycemic metabolism disease with loss of islet function. We report a case of LADA who was hospitalized at the age of 47 with type 2 DM diagnosis. The patient was informed about the case report on December 20, 2018

Anahtar Kelimeler

• Diabetes mellitus,Insulın,LADA

Kaynakça

1. 1. ADA Clinical Practice Recommendations. Diagnosis and classification of diabetes mellitus. Diabetes Care 2007;30(Suppl.1):S42-S47.
2. 2. Mc Cullough DK. Overview of medical care in adults with diabetes mellitus. Uptodate March 2015. Accessed on 4/8/2015.
3. 3. Groop LC, Bottazzo GF, Doniach D. Islet cell antibodies identify latent type I diabetes in patients aged 35-75 years at diagnosis. Diabetes. 1986;35(2):237-241.
4. 4. Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles W, Mackay IR. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes. 1993;42(2):359-362.
5. 5. Zimmet PZ, Tuomi T, Mackay IR, Rowley MJ, Knowles W, Cohen M, Lang DA. Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabet Med. 1994;11(3):299-303.
6. 6. Stenstrom G, Gottsater A, Bakhtadze E, Berger B, Sundkvist G. Latent autoimmune diabetes in adults: definition, prevalence, beta-cell function, and treatment. Diabetes. 2005;54(Suppl 2):S68-72.
7. 7. Pipi E, Marketou M, Tsirogianni A. Distinct clinical and laboratory characteristics of latent autoimmune diabetes in adults in relation to type 1 and type 2 diabetes mellitus. World J Diabetes. 2014;5(4):505-510.
8. 8. Cervin C, Lyssenko V, Bakhtadze E, Lindholm E, Nilsson P, Tuomi T, Cilio CM, et al. Genetic similarities between latent autoimmune diabetes in adults, type 1 diabetes, and type 2 diabetes. Diabetes. 2008;57(5):1433-1437.

9. 9. Maruyama T, Nakagawa T, Kasuga A, Murata M. Heterogeneity among patients with latent autoimmune diabetes in adults. Diabetes Metab Res Rev. 2011;27(8):971-974.
10. 10. Buzzetti R, Pozzilli P, Frederich R, Iqbal N, Hirshberg B. Saxagliptin improves glycaemic control and C-peptide secretion in latent autoimmune diabetes in adults (LADA). Diabetes Metab Res Rev. 2016, 32: 289-96
11. 11. Juhl CB, Bradley U, Holst JJ, Leslie RD, Yderstraede KB, Hunter S; Action LADA Consortium. Similar weight-adjusted insulin secretion and insulin sensitivity in short-duration late autoimmune diabetes of adulthood (LADA) and type 2 diabetes: Action LADA 9 [corrected]. Diabet Med. 2014, 31: 941-45
12. 12. Munakata Y, Yamada T, Takahashi K, Tsukita S, Takahashi K, Sawada S, Imai J, Ishigaki Y, Oka Y, Katagiri H. A case of slowly progressive type 1 diabetes with insulin independence maintained for 10 years with α-glucosidase inhibitor monotherapy. Intern Med 2012, 51: 3391-4
13. 13. Leslie RD, Palmer J, Schloot NC, Lernmark A. Diabetes at the crossroads: relevance of disease classification to pathophysiology and treatment. Diabetologia. 2016, 59:13-20.